NeutroFlow Consortium Secures Major Grant for Cancer Research
A European-led consortium that includes notable institutions like Heidelberg University Hospital, the European Institute of Oncology, Virgen Macarena University Hospital, and OncoHost has recently secured a significant €2.5 million grant. This funding comes under the EIC Transition Programme of Horizon Europe and is aimed at advancing the development of innovative diagnostic technologies.
Advancing Precision Medicine with NeutroFlow
The primary focus of this grant is the development of NeutroFlow, an exciting new point-of-care diagnostic test set to improve predictions regarding patients' responses to immune checkpoint inhibitors (ICIs). This test will be utilized across several cancer types including non-small cell lung cancer, renal cell carcinoma, melanoma, head and neck squamous cell carcinoma, and triple-negative breast cancer.
Leadership and Expertise
OncoHost will take the lead on this consortium, coordinating efforts to ensure successful implementation of project goals. The team comprises distinguished researchers and clinicians including Professor Petros Christopoulos, Dr. Stefanie Zschäbitz, and Dr. Sebastian Dieter from Heidelberg University. They are joined by esteemed colleagues from the European Institute of Oncology and Virgen Macarena University Hospital, contributing ample expertise in immunotherapy, clinical oncology, and translational research.
The Importance of Predictive Biomarkers
Despite the promising advancements that ICIs have brought to oncology, the reality remains that not all patients benefit from these treatments. This creates a pressing need for reliable and insightful predictive biomarkers that can enhance clinical decision-making. The NeutroFlow project aims to address this gap by utilizing groundbreaking research that identifies Ly6Ehi neutrophils as a pre-treatment biomarker, facilitating an actionable approach to immunotherapy.
Transformative Impact on Clinical Practice
By developing a flow cytometry-based test, NeutroFlow has the potential to be implemented across regular hospital settings, providing a cost-effective and scalable solution for clinicians. This testing method not only promises to optimize treatment plans but also aims to ensure that patients who are most likely to benefit from ICIs are accurately identified, improving overall outcomes.
Collaborative Commitment to Oncology
The award of this grant highlights the consortium’s dedication to pioneering advancements in the field of precision oncology. Its collaborative efforts are poised to transform access to personalized medicine, focusing on enhancing predictive, patient-centric solutions.
About the Consortium Partners
The consortium is made up of leading organizations that each contribute their unique strengths. Heidelberg University is a prominent research institution recognized for its vast contributions to life sciences and oncology. The European Institute of Oncology is acclaimed for its dedicated research and treatment strategies. Virgen Macarena University Hospital excels in clinical research and immunotherapy, while OncoHost focuses on precision medicine, advancing decision-making through innovative predictive technologies.
Frequently Asked Questions
What is NeutroFlow?
NeutroFlow is a point-of-care diagnostic test designed to predict a patient’s response to immune checkpoint inhibitors for various types of cancer.
Who is involved in the NeutroFlow consortium?
The consortium includes Heidelberg University Hospital, the European Institute of Oncology, Virgen Macarena University Hospital, and OncoHost, all of which contribute extensive expertise.
What is the purpose of the grant?
The grant aims to support the development of predictive biomarkers that enhance treatment outcomes for cancer patients undergoing immunotherapy.
How will NeutroFlow benefit patients?
NeutroFlow aims to provide a reliable method for determining which patients are most likely to respond to immunotherapy, improving overall treatment efficacy and patient care.
What role does OncoHost play in this consortium?
OncoHost leads the consortium and coordinates the various efforts focused on developing the NeutroFlow diagnostic test, leveraging its expertise in precision medicine.
